A Postmarketing Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® (ponatinib) in Routine Clinical Practice in the US (OMNI)

25/03/2015
02/07/2024
EU PAS number:
EUPAS9097
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Redacted AP24534-14-401 OMNI Protocol Amendment 4, v5.0

English (2.04 MB - PDF) View document
Study results
Study results

AP24534-14-401 Clinical Study Report Synoptic Body_Redacted

English (858.25 KB - PDF) View document
Study report
Other information